Oncotarget

Research Papers:

Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma

Cheng-Lung Hsu _, Yung-Chia Kuo, Yenlin Huang, Yin-Cheng Huang, Kar-Wai Lui, Kai-Ping Chang, Tung-Liang Lin, Hsien-Chi Fan, An-Chi Lin, Chia-Hsun Hsieh, Li-Yu Lee, Hung-Ming Wang, Hsin-Pai Li and Yu-Sun Chang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31323-31334. https://doi.org/10.18632/oncotarget.5544

Metrics: PDF 2723 views  |   HTML 1278 views  |   ?  


Abstract

Cheng-Lung Hsu1, Yung-Chia Kuo1, Yenlin Huang2, Yin-Cheng Huang3, Kar-Wai Lui4, Kai-Ping Chang5, Tung-Liang Lin1, Hsien-Chi Fan1, An-Chi Lin1, Chia-Hsun Hsieh1, Li-Yu Lee2, Hung-Ming Wang1, Hsin-Pai Li6, Yu-Sun Chang6

1Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan, ROC

2Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan, ROC

3Division of Neurologic Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan, ROC

4Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan, ROC

5Department of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan, ROC

6Department of Cell and Molecular Biology, Chang Gung University, Taoyuan 333, Taiwan, ROC

Correspondence to:

Cheng-Lung Hsu, e-mail: hsu2221@adm.cgmh.org.tw

Keywords: NPC, PDX, EBV, target therapy, viral lytic therapy

Received: July 09, 2015     Accepted: September 11, 2015     Published: September 24, 2015

ABSTRACT

Nasopharyngeal carcinoma (NPC) is an Epstein Barr virus (EBV)-related malignancy in which the tumor microenvironment plays a pivotal role in tumor progression. Here, we developed two patient-derived xenograft (PDX) mouse lines from engrafted NPC metastatic tumors. Positive staining for EBV-encoded small RNAs confirmed that these tumors harbored EBV, and gene expression profile analyses further showed that the PDX was highly similar to the primary parent tumor. In vivo drug screening using the PDX system demonstrated that gemcitabine had the best antitumor effect among the tested drugs. The donor of this PDX also showed excellent responsiveness to gemcitabine treatment. The combination of gemcitabine and valproic acid exerted synergistic antitumor effects. Further addition of ganciclovir to this two-drug combination regimen enhanced cytolytic viral activation, yielding the best antitumor response among tested regimens. Treatment with this three-drug combination regimen decreased plasma EBV-DNA load, tumor viral concentration, and the number of viable tumor cells to a greater extent than the two-drug gemcitabine and valproic acid combination. These results highlight the value of PDX models in the development of EBV-targeted strategies to treat NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5544